Agenus Inc. (NASDAQ:AGEN – Free Report) – HC Wainwright increased their Q2 2026 EPS estimates for shares of Agenus in a report issued on Tuesday, May 12th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will earn $0.06 per share for the quarter, up from their previous forecast of ($0.32). The consensus estimate for Agenus’ current full-year earnings is $2.10 per share. HC Wainwright also issued estimates for Agenus’ Q3 2026 earnings at $0.05 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at $1.07 EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at ($0.56) EPS, FY2029 earnings at ($0.34) EPS and FY2030 earnings at $0.09 EPS.
Other analysts also recently issued reports about the stock. Zacks Research downgraded shares of Agenus from a “strong-buy” rating to a “hold” rating in a report on Monday. Wall Street Zen raised shares of Agenus from a “hold” rating to a “buy” rating in a report on Monday, April 6th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $14.50.
Agenus Stock Performance
Shares of NASDAQ AGEN opened at $3.47 on Thursday. The company’s fifty day moving average price is $3.72 and its 200 day moving average price is $3.66. Agenus has a 1 year low of $2.71 and a 1 year high of $7.34. The company has a market capitalization of $144.49 million, a PE ratio of 2.18 and a beta of 1.60.
Agenus (NASDAQ:AGEN – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.10 by ($1.08). Agenus had a negative return on equity of 31.66% and a net margin of 50.49%.The firm had revenue of $33.70 million for the quarter, compared to analysts’ expectations of $129.50 million.
Hedge Funds Weigh In On Agenus
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. LPL Financial LLC lifted its holdings in Agenus by 20.3% during the fourth quarter. LPL Financial LLC now owns 23,326 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 3,943 shares in the last quarter. EP Wealth Advisors LLC purchased a new position in Agenus during the fourth quarter valued at $31,000. Jump Financial LLC purchased a new position in Agenus during the second quarter valued at $55,000. Traynor Capital Management Inc. purchased a new position in Agenus during the third quarter valued at $50,000. Finally, R Squared Ltd purchased a new position in Agenus during the fourth quarter valued at $41,000. 61.46% of the stock is owned by hedge funds and other institutional investors.
More Agenus News
Here are the key news stories impacting Agenus this week:
- Positive Sentiment: HC Wainwright raised its FY2027 earnings estimate for Agenus, suggesting a better medium-term profit outlook than previously expected.
- Positive Sentiment: HC Wainwright also increased FY2028, FY2029 and FY2030 EPS estimates, indicating improving expectations further out.
- Positive Sentiment: The firm lifted its Q2 2026 EPS forecast, showing some near-term improvement versus prior estimates.
- Neutral Sentiment: HC Wainwright cut its Q3 and Q4 2026 EPS estimates, reflecting a more cautious view on results later this year.
- Neutral Sentiment: HC Wainwright reduced its FY2026 EPS estimate, implying a lower full-year profit outlook even though the stock already trades at a low valuation.
- Negative Sentiment: Zacks Research downgraded Agenus from strong-buy to hold, which likely weighed on investor sentiment.
- Negative Sentiment: The company’s recent earnings report missed expectations, with Q1 EPS and revenue both coming in well below consensus, reinforcing concerns about execution.
Agenus Company Profile
Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.
Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.
See Also
- Five stocks we like better than Agenus
- Oklo Stock Could Be Ready for Another Massive Run
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
